These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 17314232)

  • 1. Long-lasting protective immune response to the 19-kilodalton carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 in mice.
    Jeamwattanalert P; Mahakunkijcharoen Y; Kittigul L; Mahannop P; Pichyangkul S; Hirunpetcharat C
    Clin Vaccine Immunol; 2007 Apr; 14(4):342-7. PubMed ID: 17314232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A single injection of 19 kda carboxy-terminal fragment of Plasmodium yoelii merozoite surface protein 1 (PyMSP1(19)) formulated with Montanide ISA and CpG ODN induces protective immune response in mice.
    Hirunpetcharat C; Mahakunkijcharoen Y; Jeamwattanalert P; Kittigul L; Mahannop P; Pichyangkul S
    Asian Pac J Allergy Immunol; 2011 Sep; 29(3):252-9. PubMed ID: 22053595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides.
    Hirunpetcharat C; Wipasa J; Sakkhachornphop S; Nitkumhan T; Zheng YZ; Pichyangkul S; Krieg AM; Walsh DS; Heppner DG; Good MF
    Vaccine; 2003 Jun; 21(21-22):2923-32. PubMed ID: 12798636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevisiae: correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells.
    Hirunpetcharat C; Tian JH; Kaslow DC; van Rooijen N; Kumar S; Berzofsky JA; Miller LH; Good MF
    J Immunol; 1997 Oct; 159(7):3400-11. PubMed ID: 9317139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
    Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin.
    Bargieri DY; Rosa DS; Braga CJ; Carvalho BO; Costa FT; Espíndola NM; Vaz AJ; Soares IS; Ferreira LC; Rodrigues MM
    Vaccine; 2008 Nov; 26(48):6132-42. PubMed ID: 18804504
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite.
    Kang Y; Calvo PA; Daly TM; Long CA
    J Immunol; 1998 Oct; 161(8):4211-9. PubMed ID: 9780195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute requirement for an active immune response involving B cells and Th cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19-kDa carboxyl-terminal fragment of merozoite surface protein-1.
    Hirunpetcharat C; Vukovic P; Liu XQ; Kaslow DC; Miller LH; Good MF
    J Immunol; 1999 Jun; 162(12):7309-14. PubMed ID: 10358180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant activity of polymer microparticles and Montanide ISA 720 on immune responses to Plasmodium falciparum MSP2 long synthetic peptides in mice.
    Mata E; Carcaboso AM; Hernández RM; Igartua M; Corradin G; Pedraz JL
    Vaccine; 2007 Jan; 25(5):877-85. PubMed ID: 17070628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved immunogenicity and efficacy of the recombinant 19-kilodalton merozoite surface protein 1 by the addition of oligodeoxynucleotide and aluminum hydroxide gel in a murine malaria vaccine model.
    Near KA; Stowers AW; Jankovic D; Kaslow DC
    Infect Immun; 2002 Feb; 70(2):692-701. PubMed ID: 11796601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.
    Kumar S; Jones TR; Oakley MS; Zheng H; Kuppusamy SP; Taye A; Krieg AM; Stowers AW; Kaslow DC; Hoffman SL
    Infect Immun; 2004 Feb; 72(2):949-57. PubMed ID: 14742540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
    Wang L; Goschnick MW; Coppel RL
    Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of disulphide-bridge-dependent conformational epitopes and immunogenicity of the carboxy-terminal 19 kDa domain of Plasmodium yoelii merozoite surface protein-1 in live attenuated Salmonella vaccine strains.
    Somner EA; Ogun SA; Sinha KA; Spencer Valero LM; Lee JJ; Harrison JA; Holder AA; Hormaeche CE; Khan ACM
    Microbiology (Reading); 1999 Jan; 145 ( Pt 1)():221-229. PubMed ID: 10206702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
    Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
    Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant Mycobacterium bovis bacillus Calmette-Guérin secreting merozoite surface protein 1 (MSP1) induces protection against rodent malaria parasite infection depending on MSP1-stimulated interferon gamma and parasite-specific antibodies.
    Matsumoto S; Yukitake H; Kanbara H; Yamada T
    J Exp Med; 1998 Sep; 188(5):845-54. PubMed ID: 9730886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antigenicity and immunogenicity of the N-terminal 33-kDa processing fragment of the Plasmodium falciparum merozoite surface protein 1, MSP1: implications for vaccine development.
    Yuen D; Leung WH; Cheung R; Hashimoto C; Ng SF; Ho W; Hui G
    Vaccine; 2007 Jan; 25(3):490-9. PubMed ID: 16949181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
    Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
    Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasmodium: immunization with carboxyl-terminal regions of MSP-1 protects against homologous but not heterologous blood-stage parasite challenge.
    Rotman HL; Daly TM; Long CA
    Exp Parasitol; 1999 Jan; 91(1):78-85. PubMed ID: 9920045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune responses elicited by co-immunization of Plasmodium vivax and P. falciparum MSP-1 using prime-boost immunization strategies.
    Mehrizi AA; Zakeri S; Rafati S; Salmanian AH; Djadid ND
    Parasite Immunol; 2011 Nov; 33(11):594-608. PubMed ID: 21883290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines.
    ten Hagen TL; Sulzer AJ; Kidd MR; Lal AA; Hunter RL
    J Immunol; 1993 Dec; 151(12):7077-85. PubMed ID: 8258712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.